- Home
- LUCD vs QNCX Comparison
LUCD vs QNCX Comparison
Compare LUCD & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCD
- QNCX
- Stock Information
- Founded
- LUCD 2018
- QNCX 2012
- Country
- LUCD United States
- QNCX United States
- Employees
- LUCD N/A
- QNCX N/A
- Industry
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LUCD Health Care
- QNCX Health Care
- Exchange
- LUCD Nasdaq
- QNCX Nasdaq
- Market Cap
- LUCD 108.0M
- QNCX 88.6M
- IPO Year
- LUCD 2021
- QNCX 2019
- Fundamental
- Price
- LUCD $1.13
- QNCX $1.70
- Analyst Decision
- LUCD Strong Buy
- QNCX Strong Buy
- Analyst Count
- LUCD 5
- QNCX 4
- Target Price
- LUCD $3.70
- QNCX $7.75
- AVG Volume (30 Days)
- LUCD 637.8K
- QNCX 334.7K
- Earning Date
- LUCD 11-12-2025
- QNCX 11-12-2025
- Dividend Yield
- LUCD N/A
- QNCX N/A
- EPS Growth
- LUCD N/A
- QNCX N/A
- EPS
- LUCD N/A
- QNCX N/A
- Revenue
- LUCD $4,399,000.00
- QNCX N/A
- Revenue This Year
- LUCD $13.30
- QNCX N/A
- Revenue Next Year
- LUCD $155.58
- QNCX N/A
- P/E Ratio
- LUCD N/A
- QNCX N/A
- Revenue Growth
- LUCD 5.01
- QNCX N/A
- 52 Week Low
- LUCD $0.75
- QNCX $0.72
- 52 Week High
- LUCD $1.80
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- LUCD 47.07
- QNCX 51.06
- Support Level
- LUCD $1.03
- QNCX $1.44
- Resistance Level
- LUCD $1.23
- QNCX $1.84
- Average True Range (ATR)
- LUCD 0.06
- QNCX 0.12
- MACD
- LUCD -0.02
- QNCX -0.00
- Stochastic Oscillator
- LUCD 34.62
- QNCX 64.37
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.